NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Exai Bio

Exai Bio

Private
Palo Alto, CaliforniaHealthcare & Life Scienceshttps://www.exai.bio/

Last Round

Grant

Sep 19, 2024

Est. Valuation

$130.6M

Total Funding Raised

$140.74M

Company Overview

Exai Bio is a biotechnology company that develops a liquid biopsy platform utilizing oncRNA technology and artificial intelligence for early cancer detection and personalized treatment guidance.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

liquid biopsycancer detectioncell-free RNAcfRNAoncology diagnosticsprecision medicinebiomarker discoverycompanion diagnosticscancer monitoringAI diagnosticsmulti-cancer detectionblood-based cancer testfoundation modelfrontier ai lab

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Exai Bio Comparables

Compare Exai Bio with similar companies based on industry and business-model similarity.

Exai Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Precede Biosciences
86%
Flomics Biotech
83%
Hummingbird Diagnostics GmbH
83%

Exai Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantSep 19, 2024
GrantSep 25, 2023
Series A ExtensionOct 1, 2022
Series ADec 9, 2021
GrantApr 1, 2018

Key People

Founding team and executive leadership

Michael Nall

CEO and Board Member

Executive Team

Exai Bio Investors

Notable investors and investment history

Exai Bio investors
InvestorRounds
S32Series A, Series A Extension
National Cancer InstituteGrant
NIH RADxGrant
Blue Cross Blue Shield AssociationSeries A
Moore Strategic VenturesSeries A Extension
Two Sigma VenturesSeries A, Series A Extension
Casdin CapitalSeries A, Series A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 1, 2022

    $71M round led by S32 and Casdin Capital.

  • Dec 9, 2021

    $68M round led by S32 and Casdin Capital.

Exai Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Exai Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Exai Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersPalo Alto, California
Employee Range22
Year Founded2021
Last FundingSep 19, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.